

CKCis Publications as of August 2025

50 Publications

1. Lavallée LT, Tanguay S, Jewett MA, Wood L, Kapoor A, Rendon RA, Moore RB, Lacombe L, Kawakami J, Pautler SE, Drachenberg DE, Black PC, Lattouf JB, Morash C, Cagiannos I, Liu Z, Breau RH. **Surgical management of stage T1 renal tumours at Canadian academic centres.** Can Urol Assoc J. 2015 Mar-Apr;9(3-4):99-106. doi: 10.5489/cuaj.2598. Erratum in: Can Urol Assoc J. 2016 Aug;10(7-8):E281. doi: 10.5489/cuaj.4046. PMID: 26085866; PMCID: PMC4455632.
2. Nayak JG, Patel P, Bjazevic J, Liu Z, Saarela O, Kapoor A, Rendon R, Kawakami J, Tanguay S, Breau RH, Black PC, Drachenberg DE. **Clinical outcomes following laparoscopic management of pT3 renal masses: A large, multi-institutional cohort.** Can Urol Assoc J. 2015 Nov-Dec;9(11-12):397-402. doi: 10.5489/cuaj.2848. Epub 2015 Dec 14. PMID: 26788228; PMCID: PMC4707891.
3. Forbes CM, Rendon RA, Finelli A, Kapoor A, Moore RB, Breau RH, Lacombe L, Kawakami J, Drachenberg DE, Pautler SE, Jewett MMA, Saarela O, Liu Z, Tanguay S, Black PC. **Disease progression and kidney function after partial vs. radical nephrectomy for T1 renal cancer.** Urol Oncol. 2016 Nov;34(11):486.e17-486.e23. doi: 10.1016/j.urolonc.2016.05.034. Epub 2016 Jul 14. PMID: 27423824.
4. Mason R, Kapoor A, Liu Z, Saarela O, Tanguay S, Jewett M, Finelli A, Lacombe L, Kawakami J, Moore R, Morash C, Black P, Rendon RA. **The natural history of renal function after surgical management of renal cell carcinoma: Results from the Canadian Kidney Cancer Information System.** Urol Oncol. 2016 Nov;34(11):486.e1-486.e7. doi: 10.1016/j.urolonc.2016.05.025. Epub 2016 Jun 22. Erratum in: Urol Oncol. 2017 Mar;35(3):124. doi: 10.1016/j.urolonc.2017.01.018. PMID: 27344410.
5. Richard PO, Jewett MA, Tanguay S, Saarela O, Liu ZA, Pouliot F, Kapoor A, Rendon R, Finelli A. **Safety, reliability and accuracy of small renal tumour biopsies: results from a multi-institution registry.** BJU Int. 2017 Apr;119(4):543-549. doi: 10.1111/bju.13630. Epub 2016 Sep 7. PMID: 27528446.

6. Nayak JG, Patel P, Saarela O, Liu Z, Kapoor A, Finelli A, Tanguay S, Rendon R, Moore R, Black PC, Lacombe L, Breau RH, Kawakami J, Drachenberg DE. **Pathological Upstaging of Clinical T1 to Pathological T3a Renal Cell Carcinoma: A Multi-institutional Analysis of Short-term Outcomes.** Urology. 2016 Aug;94:154-60. doi: 10.1016/j.urology.2016.03.029. Epub 2016 Mar 31. PMID: 27041471.
7. Lawson KA, Saarela O, Liu Z, Lavallée LT, Breau RH, Wood L, Jewett MAS, Kapoor A, Tanguay S, Moore RB, Rendon R, Pouliot F, Black PC, Kawakami J, Drachenberg D, Finelli A. **Benchmarking quality for renal cancer surgery: Canadian Kidney Cancer information system (CKCis) perspective.** Can Urol Assoc J. 2017 Aug;11(8):232-237. doi: 10.5489/cuaj.4397. PMID: 28798821; PMCID: PMC5542828.
8. Patel P, Nayak JG, Liu Z, Saarela O, Jewett M, Rendon R, Kapoor A, Black P, Tanguay S, Kawakami J, Moore R, Breau RH, Morash C, Pouliot F, Drachenberg DE. **A Multicentered, Propensity Matched Analysis Comparing Laparoscopic and Open Surgery for pT3a Renal Cell Carcinoma.** J Endourol. 2017 Jul;31(7):645-650. doi: 10.1089/end.2016.0787. PMID: 28381117.
9. Bansal RK, Tanguay S, Finelli A, Rendon R, Moore RB, Breau RH, Lacombe L, Black PC, Kawakami J, Drachenberg D, Pautler S, Saarela O, Liu Z, Jewett MAS, Kapoor A. **Positive surgical margins during partial nephrectomy for renal cell carcinoma: Results from Canadian Kidney Cancer information system (CKCis) collaborative.** Can Urol Assoc J. 2017 Jun;11(6):182-187. doi: 10.5489/cuaj.4264. PMID: 28652876; PMCID: PMC5472463.
10. Lalani AA, Li H, Heng DYC, Wood L, Kalirai A, Bjarnason GA, Sim HW, Kollmannsberger CK, Kapoor A, Hotte SJ, Vanhuysse M, Czaykowski P, Reaume MN, Soulieres D, Venner P, North S, Basappa NS. **First-line sunitinib or pazopanib in metastatic renal cell carcinoma: The Canadian experience.** Can Urol Assoc J. 2017 Mar-Apr;11(3-4):112-117. doi: 10.5489/cuaj.4398. PMID: 28515811; PMCID: PMC5434501.
11. Dragomir A, Aprikian A, Kapoor A, Finelli A, Pouliot F, Rendon R, Black PC, Moore R, Breau RH, Kawakami J, Drachenberg D, Lattouf JB, Tanguay S. **Follow-up imaging after nephrectomy for cancer in Canada: urologists' compliance with guidelines. An observational study.** CMAJ Open. 2017 Dec 11;5(4):E834-E841. doi: 10.9778/cmajo.20170005. PMID: 29229610; PMCID: PMC5741415.

12. Nazha S, Tanguay S, Kapoor A, Jewett M, Kollmannsberger C, Wood L, Bjarnason G, Heng D, Soulières D, Reaume N, Basappa N, Lévesque E, Dragomir A. **Use of targeted therapy in patients with metastatic renal cell carcinoma: clinical and economic impact in a Canadian real-life setting.** *Curr Oncol.* 2018 Dec;25(6):e576-e584. doi: 10.3747/co.25.4103. Epub 2018 Dec 1. PMID: 30607126; PMCID: PMC6291289.

13. Nazha S, Tanguay S, Kapoor A, Jewett M, Kollmannsberger C, Wood L, Bjarnason GAG, Heng D, Soulières D, Reaume MN, Basappa N, Lévesque E, Dragomir A. **Cost-utility of Sunitinib Versus Pazopanib in Metastatic Renal Cell Carcinoma in Canada using Real-world Evidence.** *Clin Drug Investig.* 2018 Dec;38(12):1155-1165. doi: 10.1007/s40261-018-0705-6. PMID: 30267257.

14. Marconi L, de Bruijn R, van Werkhoven E, Beisland C, Fife K, Heidenreich A, Kapoor A, Karam J, Kauffmann C, Klatte T, Ljungberg B, Matin S, Sjöberg D, Staehler M, Stewart GD, Tanguay S, Uzzo R, Welsh S, Wood L, Wood C, Bex A. **External validation of a predictive model of survival after cytoreductive nephrectomy for metastatic renal cell carcinoma.** *World J Urol.* 2018 Dec;36(12):1973-1980. doi: 10.1007/s00345-018-2427-z. Epub 2018 Aug 1. PMID: 30069581.

15. Wong ECL, Breau RH, Mallick R, Wood L, Pouliot F, Basappa NS, Tanguay S, Soulières D, So A, Heng D, Lavallée LT, Drachenberg D, Kapoor A. **Renal cell carcinoma in the Canadian Indigenous population.** *Curr Oncol.* 2019 Jun;26(3):e367-e371. doi: 10.3747/co.26.4707. Epub 2019 Jun 1. PMID: 31285681; PMCID: PMC6588075.

16. Nayan M, Jalali S, Kapoor A, Finelli A, So A, Rendon R, Breau RH, Lavallee LT, Tanguay S, Heng D, Kawakami J, Basappa NS, Bjarnason G, Pouliot F, Hamilton RJ. **Diabetes and kidney cancer survival in patients undergoing nephrectomy: A Canadian multi-center, propensity score analysis.** *Urol Oncol.* 2019 Sep;37(9):576.e11-576.e16. doi: 10.1016/j.urolonc.2019.06.006. Epub 2019 Jul 5. PMID: 31285115.

17. Kushnir I, Kirk L, Mallick R, Kim RH, Graham GE, Breau RH, Lattouf JB, Violette PD, Pautler SE, Care M, Kapoor A, Jewett MAS, Wood L, Tanguay S, Heng DYC, Basappa NS, So A, Pouliot F, Reaume NM. **Application of Hereditary Renal Cell Carcinoma Risk Criteria to a Large Prospective Database.** *Clin Oncol (R Coll Radiol).* 2020 Jan;32(1):e10-e15. doi: 10.1016/j.clon.2019.07.010. Epub 2019 Aug 1. PMID: 31378448.

18. Oake JD, Patel P, Lavallée LT, Lattouf JB, Saarela O, Klotz L, Moore RB, Kapoor A, Finelli A, Rendon RA, Kawakami J, So AI, Drachenberg DE. **Outcomes and prognosticators of stage 4 renal cell carcinoma with pathological T4 primary lesion using a large, Canadian, multi-institutional database.** Can Urol Assoc J. 2020 Feb;14(2):24-30. doi: 10.5489/cuaj.5941. Epub 2019 Jul 23. PMID: 31348746; PMCID: PMC7012283.
19. Wong ECL, Di Lena R, Breau RH, Pouliot F, Finelli A, Lavallée LT, So A, Tanguay S, Fairey A, Rendon R, Richard PO, Lattouf JB, Kawakami J, Mallick R, Kapoor A. **Morphologic subtyping as a prognostic predictor for survival in papillary renal cell carcinoma: Type 1 vs. type 2.** Urol Oncol. 2019 Oct;37(10):721-726. doi: 10.1016/j.urolonc.2019.05.009. Epub 2019 Jun 5. PMID: 31176614.
20. Shiff B, Breau RH, Patel P, Mallick R, Tanguay S, So A, Lavallée L, Moore R, Rendon R, Kapoor A, Pouliot F, Finelli A, Bhindi B, Lattouf JB, Basappa N, Wood L, Heng D, Bjarnason G, Drachenberg D. **Impact of Time to Surgery and Surgical Delay on Oncologic Outcomes for Renal Cell Carcinoma.** J Urol. 2021 Jan;205(1):78-85. doi: 10.1097/JU.0000000000001230. Epub 2020 Jul 2. PMID: 32614274.
21. Ghavimi S, Saarela O, Pouliot F, Rendon RA, Finelli A, Kapoor A, Moore RB, Breau RH, Lavallée L, Lacombe L, Fairey A, Jewett M, Liu Z, Tanguay S, Black PC. **Achieving the "trifecta" with open versus minimally invasive partial nephrectomy.** World J Urol. 2021 May;39(5):1569-1575. doi: 10.1007/s00345-020-03349-y. Epub 2020 Jul 12. PMID: 32656670.
22. Asselin C, Finelli A, Breau RH, Mallick R, Kapoor A, Rendon RA, Tanguay S, Pouliot F, Fairey A, Lavallée LT, Bladou F, Kawakami J, So AI, Richard PO. **Does renal tumor biopsies for small renal carcinoma increase the risk of upstaging on final surgery pathology report and the risk of recurrence?** Urol Oncol. 2020 Oct;38(10):798.e9-798.e16. doi: 10.1016/j.urolonc.2020.06.001. Epub 2020 Jul 18. PMID: 32693974.
23. Dragomir A, Nazha S, Wood LA, Rendon RA, Finelli A, Hansen A, So AI, Kollmannsberger C, Basappa NS, Pouliot F, Soulières D, Heng DYC, Kapoor A, Tanguay S. **Outcomes of complete metastasectomy in metastatic renal cell carcinoma patients: The Canadian Kidney Cancer information system experience.** Urol Oncol. 2020 Oct;38(10):799.e1-799.e10. doi: 10.1016/j.urolonc.2020.07.021. Epub 2020 Aug 7. PMID: 32778475.

24. Tajzler C, Tanguay S, Mallick R, Ahrens B, Ly TL, Breau RH, Basappa NS, Kapoor A, Heng DY, Pouliot F, Finelli A, Lavallée LT, So AI, Drachenberg DE, Soulières D, Bjarnason GA, Richard PO, Maloni R, Power NE, Haan M, Wood LA. **Determining generalizability of the Canadian Kidney Cancer information system (CKCis) to the entire Canadian kidney cancer population.** Can Urol Assoc J. 2020 Oct;14(10):E499-E506. doi: 10.5489/cuaj.6716. PMID: 33275557; PMCID: PMC7716824.

25. Sun R, Breau RH, Mallick R, Tanguay S, Pouliot F, Kapoor A, Lavallée LT, Finelli A, So AI, Rendon RA, Fairey AS, Lattouf JB, Kawakami J, Bhindi B, Basappa NS, Wood LA, Bjarnason GA, Heng DY, Bansal RK. **Prognostic impact of paraneoplastic syndromes on patients with non-metastatic renal cell carcinoma undergoing surgery: Results from Canadian Kidney Cancer information system.** Can Urol Assoc J. 2021 Apr;15(4):132-137. doi: 10.5489/cuaj.6833. PMID: 33007184; PMCID: PMC8021432.

26. Dragomir A, Hesswani C, Marcq G, So AI, Kollmannsberger C, Basappa NS, Fairey A, Kapoor A, Lalani AK, Finelli A, Wood LA, Heng DY, Bjarnason G, Breau RH, Lavallée LT, Soulières D, Drachenberg D, Pouliot F, Tanguay S. **Can incomplete metastectomy impact renal cell carcinoma outcomes? A propensity score matching analysis from a prospective multicenter collaboration.** Soc Int Urol J. 2021; 2(2)82-95.

27. Zhang H, Basappa NS, Ghosh S, Joy I, Lalani AK, Hansen AR, Heng DY, Castonguay V, Kollmannsberger CK, Winquist E, Wood L, Bjarnason GA, Breau RH, Kapoor A, Graham J. **Real-world experience of cabozantinib in metastatic renal cell carcinoma (mRCC): results from the Canadian Kidney Cancer information system (CKCis).** Kidney Cancer 2021; 5(1)21-29.

28. Kokorovic A, Breau RH, Kapoor A, Finelli A, So AI, Lavallée LT, Tanguay S, Pouliot F, Drachenberg DE, Fairey A, Lattouf JB, Kawakami J, Wood L, Mallick R, Rendon RA. **Lymph node dissection during radical nephrectomy: A Canadian multi-institutional analysis.** Urol Oncol. 2021 Jun;39(6):371.e17-371.e25. doi: 10.1016/j.urolonc.2021.02.025. Epub 2021 Mar 27. PMID: 33785219.

29. Lavi A, Breau RH, Mallick R, Kapoor A, Finelli A, So A, Pouliot F, Tanguay S, Lavallée LT, Rendon R, Fairey A, Drachenberg DE, Lattouf JB, Maloni R, Power NE. **Adrenalectomy During Radical Nephrectomy- Incidence and Oncologic Outcomes From the Canadian Kidney Cancer Information System (CKCis) -A Modern Era, Nationwide, Multicenter Cohort.** Urology. 2021 Nov;157:168-173. doi: 10.1016/j.urology.2021.05.053. Epub 2021 Jun 12. PMID: 34129893.

30. Couture F, Finelli T, Breau RH, Mallick R, Bhindi B, Tanguay S, Kapoor A, Rendon RA, Pouliot F, Lavallée L, Fairey AS, So A, Richard PO. **The increasing use of renal tumor biopsy amongst Canadian urologists: When is biopsy most utilized?** Urol Oncol. 2021 Aug;39(8):499.e15-499.e22. doi: 10.1016/j.urolonc.2021.05.026. Epub 2021 Jun 27. PMID: 34187749.

31. Shiff B, Breau RH, Mallick R, Pouliot F, So A, Tanguay S, Kapoor A, Lattouf JB, Lavallée L, Fairey A, Finelli A, Bhindi B, Kawakami J, Rendon R, Bansal RK. **Prognostic significance of extent of venous tumor thrombus in patients with non-metastatic renal cell carcinoma: Results from a Canadian multi-institutional collaborative.** Urol Oncol. 2021 Dec;39(12):836.e19-836.e27. doi: 10.1016/j.urolonc.2021.08.016. Epub 2021 Oct 20. PMID: 34556430.

32. Kushnir I, Basappa NS, Ghosh S, Lalani AA, Hansen AR, Wood L, Kollmannsberger CK, Heng DY, Bjarnason GA, Soulières D, Dawe DE, Tanguay S, Breau RH, Pouliot F, Kapoor A, Graham J, Reaume MN. **Active Surveillance in Metastatic Renal Cell Carcinoma: Results From the Canadian Kidney Cancer Information System.** Clin Genitourin Cancer. 2021 Dec;19(6):521-530. doi: 10.1016/j.clgc.2021.05.004. Epub 2021 May 15. PMID: 34158246.

33. Nguyen EK, Lalani AKA, Ghosh S, Basappa NS, Kapoor A, Hansen AR, Kollmannsberger C, Heng D, Wood LA, Castonguay V, Soulières D, Winkquist E, Canil C, Graham J, Bjarnason GA, Breau RH, Pouliot F, Swaminath A. **Outcomes of Radiation Therapy Plus Immunotherapy in Metastatic Renal Cell Carcinoma: Results From the Canadian Kidney Cancer Information System.** Adv Radiat Oncol. 2022 Jan 16;7(4):100899. doi: 10.1016/j.adro.2022.100899. PMID: 35814860; PMCID: PMC9260099.

34. Thana M, Basappa NS, Ghosh S, Kollmannsberger CK, Heng DY, Hansen AR, Graham J, Soulières D, Reaume MN, Lalani AA, Castonguay V, Bjarnason GA, Patenaude F, Breau RH, Pouliot F, Kapoor A, Wood LA. **Utilization and Safety of Ipilimumab Plus Nivolumab in a Real-World Cohort of Metastatic Renal Cell Carcinoma Patients.** Clin Genitourin Cancer. 2022 Jun;20(3):210-218. doi: 10.1016/j.clgc.2021.12.003. Epub 2021 Dec 10. PMID: 35115252.

35. Kim SSY, Breau R, Mallick R, Kapoor A, Finelli A, Pouliot F, Tanguay S, Fairey A, Bhindi B, Lavallee L, So A, Rendon R. **Ultrasound Correlates Highly With Cross Sectional Imaging for Small Renal Masses in a Contemporary Cohort.** Urology. 2022 Jul;165:212-217. doi: 10.1016/j.urology.2022.02.020. Epub 2022 Mar 6. PMID: 35263645.

36. Millan B, Breau RH, Bhindi B, Mallick R, Tanguay S, Finelli A, Lavallée LT, Pouliot F, Rendon R, So AI, Dean L, Lattouf JB, Basappa NS, Kapoor A. **A Comparison of Percutaneous Ablation Therapy to Partial Nephrectomy for cT1a Renal Cancers: Results from the Canadian Kidney Cancer Information System.** J Urol. 2022 Oct;208(4):804-812. doi: 10.1097/JU.0000000000002798. Epub 2022 Jun 10. PMID: 35686812.

37. Dragomir A, Nazha S, Tanguay S, Breau RH, Bhindi B, Rendon RA, Kapoor A, Hotte SJ, Basappa N, Fairey A, So AI, Kollmannsberger C, Finelli A, Hansen A, Canil C, Heng D, Lattouf JB, Bjarnason G, Power N, Pouliot F, Wood LA. **Outcomes of Cytoreductive Nephrectomy for Patients with Metastatic Renal Cell Carcinoma: Real World Data from Canadian Centers.** Eur Urol Focus. 2022 Nov;8(6):1703-1710. doi: 10.1016/j.euf.2021.10.004. Epub 2021 Nov 1. PMID: 34736870.

38. Parmar A, Ghosh S, Sahgal A, Lalani AA, Hansen AR, Reaume MN, Wood L, Basappa NS, Heng DY, Graham J, Kollmannsberger C, Soulières D, Breau RH, Tanguay S, Kapoor A, Pouliot F, Bjarnason GA. **Evaluating the impact of early identification of asymptomatic brain metastases in metastatic renal cell carcinoma.** Cancer Rep (Hoboken). 2023 Mar;6(3):e1763. doi: 10.1002/cnr2.1763. Epub 2022 Dec 14. PMID: 36517084; PMCID: PMC10026314.

39. Millan B, Breau RH, Mallick R, Wood L, Rendon R, Finelli A, So AI, Lavallée LT, Pouliot F, Bhindi B, Heng D, Drachenberg D, Tanguay S, Dean L, Basappa NS, Lattouf JB, Bjarnason G, Lalani AK, Kapoor A. **Comparison of patients with renal cell carcinoma in adjuvant therapy trials to a real-world population.** Urol Oncol. 2023 Jul;41(7):328.e15-328.e23. doi: 10.1016/j.urolonc.2023.04.015. Epub 2023 May 16. PMID: 37202328.
40. Cardenas LM, Ghosh S, Finelli A, Wood L, Kollmannsberger C, Basappa N, Graham J, Heng D, Bjarnason G, Soulières D, Bossé D, Castonguay V, Saleh R, Tanguay S, Bhindi B, Breau RH, Pouliot F, Lalani AA. **Trends of Utilization of Systemic Therapies for Metastatic Renal Cell Carcinoma in the Canadian Health Care System.** JCO Glob Oncol. 2023 Sep;9:e2300271. doi: 10.1200/GO.23.00271. PMID: 37992270; PMCID: PMC10681568.
41. Lemire F, Zhang M, Anderson P, Finelli A, Rendon RA, Tanguay S, Bansal R, Bhindi B, So AI, Pouliot F, Dean L, Mallick R, Lavallée LT, Breau RH. **The impact of robotic surgery access on the management of patients with clinical stage I kidney tumors.** Can Urol Assoc J. 2024 Feb;18(2):55-60. doi: 10.5489/cuaj.8506. PMID: 37931286; PMCID: PMC10841563.
42. Sawaya GB, Dragomir A, Wood LA, Kollmannsberger C, Basappa NS, Kapoor A, Soulières D, Finelli A, Heng DYC, Castonguay V, Canil C, Winkquist E, Graham J, Bjarnason GA, Bhindi B, Lalani AK, Pouliot F, Breau RH, Saleh R, Tanguay S. **Real-world Assessment of Clinical Outcomes in Patients with Metastatic Renal Cell Carcinoma with or Without Sarcomatoid Features Treated with First-line Systemic Therapies.** Eur Urol Oncol. 2024 Jun;7(3):570-580. doi: 10.1016/j.euo.2023.11.016. Epub 2023 Dec 13. PMID: 38097481.
43. Graham J, Ghosh S, Breau RH, Wood L, Tanguay S, Bosse D, Lalani AK, Bhindi B, Heng D, Finelli A, Fallah-Rad N, Castonguay V, Basappa NS, Soulières D, Pouliot F, Kollmannsberger C, Bjarnason GA. **Association of Cabozantinib Dose Reductions for Toxicity With Clinical Effectiveness in Metastatic Renal Cell Carcinoma (mRCC): Results From the Canadian Kidney Cancer Information System (CKCis).** Clin Genitourin Cancer. 2024 Jun;22(3):102060. doi: 10.1016/j.clgc.2024.02.011. Epub 2024 Feb 23. PMID: 38521648.

44. Park CL, Moria FA, Ghosh S, Wood L, Bjarnason GA, Bhindi B, Heng DYC, Castonguay V, Pouliot F, Kollmannsberger CK, Bosse D, Basappa NS, Finelli A, Fallah-Rad N, Breau RH, Lalani AA, Tanguay S, Graham J, Saleh RR. **Impact of Timing of Immunotherapy and Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma: Real-World Data on Survival Outcomes from the CKCis Database.** Curr Oncol. 2024 Aug 18;31(8):4704-4712. doi: 10.3390/currncol31080351. PMID: 39195334; PMCID: PMC11353225.

45. Robert A, Mallick R, McIsaac DI, Lavallée LT, Bhindi B, Heng D, Wood LA, Rendon R, Tanguay S, Finelli A, Bansal RK, Lalani AK, Basappa N, Mannas MP, Nayak JG, Bjarnason GA, Lattouf JB, Pouliot F, Richard PO, Tajzler C, Breau RH. **Validation of Prognostic Models for Renal Cell Carcinoma Recurrence, Cancer-Specific Mortality, and All-Cause Mortality.** J Urol. 2025 Apr;213(4):455-466. doi: 10.1097/JU.0000000000004348. Epub 2024 Dec 2. PMID: 39622017.

46. Soytaş M, Dragomir A, Sawaya GB, Hesswani C, Tanguay M, Finelli A, Wood L, Rendon R, Bansal R, Lalani AK, Heng DYC, Bhindi B, Basappa NS, Dean L, So A, Nayak JG, Bjarnason G, Breau R, Lavallée L, Lattouf JB, Pouliot F, Bonert M, Tanguay S. **Is there a minimum percentage of sarcomatoid component required to affect outcomes of localised renal cell carcinoma?** BJU Int. 2025 May;135(5):818-827. doi: 10.1111/bju.16609. Epub 2024 Dec 4. PMID: 39631366; PMCID: PMC11975170.

47. Shani Shrem N, Beltran-Bless AA, Ghosh S, Tajzler C, Wood LA, Kollmannsberger C, Basappa NS, Graham J, Fallah-Rad N, Heng DYC, Soulières D, Lalani AA, Breau RH, Finelli A, Tanguay S, Bhindi B, Bjarnason G, Pouliot F, Canil C. **Real-World Efficacy and Toxicity of Ipilimumab and Nivolumab as First-Line Treatment of Metastatic Renal Cell Carcinoma (mRCC) in a Subpopulation of Elderly and Poor Performance Status Patients.** Cancers (Basel). 2025 Feb 4;17(3):522. doi: 10.3390/cancers17030522. PMID: 39941888; PMCID: PMC11816257.

48. Bou-Nehme Sawaya G, Tanguay S, Wood LA, Kollmannsberger C, Basappa NS, Bansal R, Soulières D, Finelli A, Heng DYC, Castonguay V, Canil C, Winkvist E, Graham J, Bjarnason GA, Bhindi B, Lalani AK, Pouliot F, Breau RH, Saleh R, Dragomir A. **Optimal Timing of Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma Patients Considering Sarcomatoid Status: A Real-World Study.** Clin Genitourin Cancer. 2025 Jun;23(3):102342. doi: 10.1016/j.clgc.2025.102342. Epub 2025 Apr 4. PMID: 40288275.

49. De Vries-Brilland M, Hamilou Z, Ghosh S, Heng DY, Wood LA, Basappa NS, Kollmannsberger CK, Graham J, Bhindi B, Finelli A, Bjarnason GA, Bosse D, Pouliot F, Castonguay V, Breau RH, Saleh RR, Winkvist E, Lalani AA, Soulières D. **Real-world assessment of clinical outcomes of first-line treatment in metastatic papillary Renal Cell Carcinoma.** *Oncologist*. 2025 Aug 4:oyaf240. doi: 10.1093/oncolo/oyaf240. Epub ahead of print. PMID: 40757924.
50. Lavallée LT, Finelli A, Tanguay S, Bhindi B, Wood LA, Rendon R, Bansal R, Lalani AA, Heng DY, Basappa N, Nayak JG, Bjarnason G, Pouliot F, McLarty R, Alam A, Mallick R, Breau RH. **Incidence of local treatment and metastasis during active surveillance for patients with a small renal mass in a national multicenter prospective cohort.** *J Urol*. 2025 Aug 22:101097JU00000000000004746. doi: 10.1097/JU.00000000000004746. Epub ahead of print. PMID: 40845132.

Please note that this list does not include abstracts and poster presentations